Dr. Bander on PSMA breakthroughs in prostate cancer

“Our preclinical therapy models all show us that the combination of the 2 agents [alpha and beta particles] is substantially superior to either agent alone,” says Neil H. Bander, MD.

In this video, Neil H. Bander, MD, discusses PSMA therapeutic innovations for patients with prostate cancer and how they will change diagnosis and treatment. Bander is the Bernard & Josephine Chaus professor of urologic oncology at Weill Cornell Medicine, New York City, New York.